ZYME - Zymeworks Inc.
| Previous Close | 16.86 |
| Open | 16.87 |
| Bid | 13.91 x 800 |
| Ask | 17.80 x 800 |
| Day's Range | 16.72 - 17.54 |
| 52 Week Range | 10.72 - 29.00 |
| Volume | 147,032 |
| Avg. Volume | 111,690 |
| Market Cap | 545.177M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.26 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 24.88 |
- Business Wire•23 hours ago
Daiichi Sankyo Selects Lead Candidate Built on Zymeworks’ Azymetric™ Bispecific Platform
VANCOUVER, British Columbia VANCOUVER, British Columbia & TOKYO & BASKING RIDGE, N.J.-- -- One of three bispecific immuno-oncology therapeutics being developed under the two companies’ collaboration agreements Zymeworks to receive US$3.5 million commercial license payment from Daiichi Sankyo Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, and ...
- Business Wire•3 days ago
Zymeworks to Present at Bloom Burton & Co. Healthcare Investor Conference 2019
Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming Bloom Burton & Co.
- Business Wire•11 days ago
Zymeworks Opens Phase 2 Clinical Trial for ZW25 in First-Line HER2-Expressing Metastatic Gastroesophageal Cancers
Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced it has initiated its global multicenter Phase 2 clinical trial evaluating ZW25 in combination with standard of care chemotherapy for the first-line treatment of HER2-positive metastatic gastric, gastroesophageal junction, and esophageal adenocarcinomas. “Advancing ZW25 into a Phase 2 clinical trial represents another key milestone for Zymeworks,” said Ali Tehrani, Ph.D., Zymeworks’ President & CEO. “This reaffirms our commitment to execute our ambitious drug development strategy to address unmet need in patients with HER2-expressing cancers across multiple indications and lines of therapy.
- GlobeNewswire•last month
Positive Results and New Technology Give Rise to Antibody Dominance
POINT ROBERTS, Wash. and DELTA, British Columbia, March 27, 2019 -- Investorideas.com, a leading investor news resource covering biotech and pharma stocks releases a snapshot.
- Business Wire•2 months ago
Zymeworks Reports 2018 Year-End Financial Results
Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported financial results for the year ended December 31, 2018.
- Business Wire•2 months ago
Zymeworks to Present at Barclays 2019 Global Healthcare Conference
Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming Barclays Global Healthcare Conference taking place March 12-14, 2019 in Miami Beach, Florida.
- Benzinga•3 months ago
The Daily Biotech Pulse: Regulatory Roadblock For Immunomedics, AdCom Split On Lexicon's Diabetes Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Jan. 17) Avenue Therapeutics Inc (NASDAQ: ATXI ) BioSpecifics ...
- Business Wire•3 months ago
Zymeworks Reports Second Investigational New Drug (IND)-Submission Milestone Achieved in Lilly Collaboration
VANCOUVER, British Columbia-- -- Lilly’s second immune-oncology candidate using Zymeworks’ novel Azymetric™ platform to start clinical trials Zymeworks to receive milestone payment of US$8.0 million for this second IND submission Lilly is one of eight pharma partners; INDs by others anticipated Total value of remaining potential milestones for all Zymeworks’ partnerships exceeds US$7.6 billion Zymeworks ...
- Business Wire•4 months ago
Zymeworks Highlights 2018 Achievements and Announces 2019 Priorities
Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reviewed its key 2018 accomplishments and outlined the Company’s priorities for 2019.
- Business Wire•5 months ago
Zymeworks Submits Investigational New Drug (IND) Application for ZW49 and Presents IND-Enabling Studies at the San Antonio Breast Cancer Symposium
VANCOUVER, Canada-- -- ZW49 combines Azymetric™ and ZymeLink™ technologies to broaden the therapeutic window of antibody-drug conjugates Complete tumor regressions observed in high and low HER2-expressing models Superior preclinical efficacy compared to approved HER2 ADCs Toxicology results support clinical dosing well above predicted efficacy levels Potential to address unmet need in high and low ...
- Reuters•5 months ago
BRIEF-Zymeworks, Beigene Announce License And Collaboration Agreement For Zymeworks' Her2-Targeted Therapeutic Candidates
Nov 27 (Reuters) - Beigene Ltd: * ZYMEWORKS AND BEIGENE ANNOUNCE LICENSE AND COLLABORATION AGREEMENT FOR ZYMEWORKS’ HER2-TARGETED THERAPEUTIC CANDIDATES, ZW25 AND ZW49, IN ASIA-PACIFIC AND RESEARCH AND ...
- Business Wire•5 months ago
Zymeworks and BeiGene Announce License and Collaboration Agreement for Zymeworks’ HER2-Targeted Therapeutic Candidates, ZW25 and ZW49, in Asia-Pacific and Research and License Agreement for Zymeworks’ Azymetric™ and EFECT™ Platforms Globally
BeiGene acquires exclusive development and commercial rights to Zymeworks’ bispecific candidates, ZW25 and ZW49, in Asia (excluding Japan), Australia, and New Zealand. The companies will collaborate on joint global development for selected indications. BeiGene also acquires licenses for Zymeworks’ Azymetric™ and EFECT™ platforms to develop and commercialize up to three bispecific antibody therapeutics globally directed to BeiGene's targets.
- Business Wire•5 months ago
Zymeworks Announces Updated Clinical Data for Novel Bispecific Antibody, ZW25, Presented at the EORTC-NCI-AACR Symposium
DUBLIN-- -- ZW25 Active and Well Tolerated Across Multiple HER2-expressing Tumor Types Durable Anti-Tumor Activity with Confirmed Partial Responses and Median Progression-Free Survival > Six Months 82 Percent of Heavily Pretreated Patients Experienced Disease Control Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional therapeutics, announced today the plenary ...
- GlobeNewswire•5 months ago
Recent Analysis Shows Cleveland-Cliffs, Optical Cable, Camtek, QIAGEN N.V, Value Line, and Zymeworks Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, Nov. 13, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Business Wire•6 months ago
Zymeworks to Present at Upcoming Investor Conferences
Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming Stifel 2018 Healthcare Conference taking place November 13-14, 2018 in New York, NY and at the Jefferies 2018 London Healthcare Conference taking place November 14-15, 2018 in London, England.
- Zacks•6 months ago
Zymeworks Inc. (ZYME) Reports Q3 Loss, Tops Revenue Estimates
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of 6.35% and 2.70%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire•6 months ago
Zymeworks Reports Financial Results for the Third Quarter of 2018
Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported financial results for the third quarter ended September 30, 2018.
- Business Wire•6 months ago
Zymeworks Announces Selection of ZW25 Abstract for Plenary Session Presentation at the 30th EORTC-NCI-AACR Symposium
VANCOUVER, British Columbia-- -- Results from Phase 1 trial highlight ZW25’s single agent effect in HER2-driven cancers New and updated data focus on gastroesophageal and other HER2-expressing cancers Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional therapeutics, announced today that its abstract describing new data from the Company’s adaptive Phase 1 clinical ...
- Business Wire•6 months ago
Zymeworks and LEO Pharma Enter into Bispecific Antibody Licensing and Research Collaboration
Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, and LEO Pharma A/S, a global leader in medical dermatology, have entered into a licensing and research collaboration to discover and develop bispecific antibodies targeting cytokine-receptor pathways using Zymeworks’ antibody discovery capabilities and its proprietary Azymetric™ and EFECT™ platforms. LEO Pharma will have exclusive rights to further develop and commercialize two bispecific candidates in dermatology indications, while Zymeworks retains rights to develop antibodies in all other therapeutic areas.
- Business Wire•7 months ago
Zymeworks to Webcast R&D Briefing
Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that it will webcast its R&D Briefing from 9:00 a.m. to 12:00 p.m. Eastern Time on Thursday, October 11, 2018 in New York City. Zymeworks’ management team will discuss the Company’s clinical strategy for ZW25, provide an update on its next clinical compound ZW49, and highlight its early-stage platforms and technologies. Mark Pegram, MD, is the Susy Yuan-Huey Hung Professor of Medicine (Oncology) at the Stanford University Medical Center, Director of the Stanford Cancer Institute's Breast Oncology Program, Associate Director of Clinical Research, and Associate Dean of Clinical Research Quality.
- Business Wire•7 months ago
Zymeworks to Present at Ladenburg Thalmann 2018 Healthcare Conference
Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming Ladenburg Thalmann 2018 Healthcare Conference taking place October 1-2, 2018 in New York, NY.
- Business Wire•7 months ago
Zymeworks Names Anthony Polverino, Ph.D., Executive Vice President of Early Development and Chief Scientific Officer
Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced it has named Anthony (Tony) Polverino, Ph.D., Executive Vice President of Early Development and Chief Scientific Officer. In his new role, Dr. Polverino will be instrumental in setting and driving Zymeworks’ R&D strategy.
- Business Wire•8 months ago
Zymeworks Reports IND-Submission Milestone Achieved in Lilly Collaboration
Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported the achievement of a development milestone in its collaboration with Eli Lilly and Company. In accordance with Zymeworks’ 2013 licensing and collaboration agreement with Lilly, Zymeworks will receive a milestone payment of US$2.0 million for Lilly’s submission of an IND application for a bispecific antibody enabled by Zymeworks’ proprietary Azymetric™ platform. Previously, Zymeworks announced Lilly’s nomination of two bispecific immuno-oncology drug candidates for late-stage preclinical development.
